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1. INTRODUCTION {#cam42017-sec-0001}
===============

Cervical cancer is one of the most common malignancies among women worldwide. According to Global Cancer Statistics in 2012, an estimated 527 600 new cases and 265 700 deaths were found in women worldwide; cervical cancer is recognized as the fourth most common cancer and the fourth leading cause of cancer‐related death in women and have been a major public health problem.[1](#cam42017-bib-0001){ref-type="ref"}The burden of cervical cancer in developing countries is much higher than that in developed countries. The incidence of cervical cancer was not the top 10 in developed countries, but the second in the developing countries. The mortality was the ninth in the developed countries, and the third in developing countries.[1](#cam42017-bib-0001){ref-type="ref"} Based on data in 2011‐2015 from USA, the number of new cases was 7.4 per 100 000 women per year, and the number of deaths was 2.3 per 100 000 women per year. In terms of the latest National Cancer Statistics in China, the number of new cases was 10.08 per 100 000 women per year, and the number of deaths was 2.98 per 100 000 women per year.[2](#cam42017-bib-0002){ref-type="ref"}

Human papillomavirus (HPV) infection continues to be the most common sexually transmitted disease, has been identified as a major risk factor for cervical cancer. Eighty per cent of people will get an HPV infection in their life. HPV infection continues to cause significant burden on women. Most HPV infections are asymptomatic, transient, and will clear within 1‐2 years, but those that persist can progress to precancer or cancer.[3](#cam42017-bib-0003){ref-type="ref"} Many epidemiologic studies have found that nearly 100% of patients with cervical cancer have HPV infection.[4](#cam42017-bib-0004){ref-type="ref"}, [5](#cam42017-bib-0005){ref-type="ref"}, [6](#cam42017-bib-0006){ref-type="ref"} Sexually transmitted HPV types is usually identified as two categories: (a) High‐risk HPV, which mainly include HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, are strongly associated with cervical cancer. Two of these, HPV 16 and 18, are responsible for most HPV‐caused cancers. (b) Low‐risk HPV, which mainly include HPV 6, 11, 30, 42, 43, 44, and 61, and HPV 6 and 11 cause 90% of all genital warts. HPV testing is more sensitive than cytology in the screening of cervical cancer.

As the largest developing country in the world, China has about 130 000 new cases of cervical cancer each year, accounting for about 1/4 of new cases in the world. If effective measures are not taken, it is estimated that the number of new cases of cervical cancer will increase to 187 000 by 2050.[7](#cam42017-bib-0007){ref-type="ref"} China has actively promoted the screening and prevention of cervical cancer in recent years, but the incidence and mortality of cervical cancer have remained high, and the age distribution becomes younger. Currently, the vaccines for cervical cancer are mainly targeted at tetravalent vaccine (HPV 16, 18, 6, and 11) and bivalent vaccine (HPV 16 and 18), based on the data from HPV epidemiological survey in Europe or the United States.[8](#cam42017-bib-0008){ref-type="ref"} It needs to be considered whether the vaccines are suitable for Chinese population. It is very important to understand and grasp the distribution of HPV in Chinese general population, which provides scientific basis for prevention and treatment of cervical cancer. In 2018, Zhou HL and Xu HH et al respectively published a systematic review on prevalence and distribution of HPV in patients, which has invasive carcinoma of cervix (ICC), high‐grade squamous intraepithelial lesion (HSIL), or low‐grade squamous intraepithelial lesion (LSIL).[8](#cam42017-bib-0008){ref-type="ref"}, [9](#cam42017-bib-0009){ref-type="ref"} These studies mainly studied the prevalence and distribution of HPV in patients, but did not study on general population; the results might be influenced by selection bias, which cannot indeed reflect the real situation of HPV infection in general population. Therefore, we perform this study to integrate the findings of 68 population‐based studies. The aim was to explore that (a) temporal trends and geographical patterns in the HPV infection epidemic and (b) the differences between china and foreign countries.

2. METHODS {#cam42017-sec-0002}
==========

2.1. Search strategy {#cam42017-sec-0003}
--------------------

An extensive search strategy was conducted in multiple literature databases by October 31, 2018. The literature databases included PubMed, Web of Science, Chinese Scientific Journals Full text Database (CQVIP), China National Knowledge Infrastructure (CNKI), and Wanfang Data. We set the following key words: (a) "Papillomaviridae" and free word "China" were used for PubMed and Web of Science; (b) "Papillomaviridae" was set as subject heading (including title, abstract, and keyword) to search Chinese database. We also reviewed reference lists from all the relevant original research and review studies to identify additional possibly eligible studies. This study was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement issued in 2009.[10](#cam42017-bib-0010){ref-type="ref"}

2.2. Study selection {#cam42017-sec-0004}
--------------------

We used Endnote^®^ (version X6; Thomson Reuters, Inc, Philadelphia, PA) bibliographic software to create an electronic library, which collected all the retrieved studies from literature databases. After deleting the duplicated studies by the software identification, 2 independent authors (Bo Zhu, Tingting Zuo) performed title/abstract screening and full text screening in turn. When any disagreements happened, 3 independent authors (Bo Zhu, Tingting Zuo, and Mengdan Li) reached agreement by discussion.

The inclusion and exclusion criteria were as follows: (a) the subjects of studies should come from the general population, excluded the studies that contained outpatients and/or patients; (b) for the detection of HPV infection, both high‐risk and low‐risk types must be included; (c) the methodology of HPV detection should be explicitly stated; (d) the study contained the prevalence of HPV infection, or provided the available data to calculate the estimates; (e) when 2 studies were found to be from the same population, the latest or maximum sample size article was included.

2.3. Quality assessment {#cam42017-sec-0005}
-----------------------

The methodological quality and validity of the included studies were assessed by an existing tool, which was modified to assess risk of bias in prevalence studies.[11](#cam42017-bib-0011){ref-type="ref"} Ten aspects in the tool were used to evaluate the quality of the included study, which was shown in supplementary Data [S1](#cam42017-sup-0001){ref-type="supplementary-material"}. The included studies were assessed a score of 0 (high risk) or 1 (low risk) for each aspect. The score of study quality ranged from 0‐10. The study with 8‐10 points was regarded as "high quality", the study with 4‐7 points was regarded as "moderate quality", and otherwise, the study was regarded as "low quality". The quality assessment tool is shown in supplementary Data [S1](#cam42017-sup-0001){ref-type="supplementary-material"}.

2.4. Data extraction {#cam42017-sec-0006}
--------------------

The included studies were independently read in detail by two reviewers (Bo Zhu and Tingting Zuo). Two reviewers used a fixed table to extract the information, which included the following: first author and year of publication, sample size, age, study period, region classification, and province.

2.5. Statistical analysis {#cam42017-sec-0007}
-------------------------

Stata software package (Version 12.0; Stata Corp., College Station, TX) was used in the pooled analysis. The random effects model (DerSimonian‐Laird) was used to pool the study‐specific estimates to obtain an overall summary estimate of the prevalence of HPV infection. In order to fully reflect the distribution of HPV infection in China, we performed subgroup analysis by age, geographic location, the level of economic development, HPV assay method, and type of HPV infection. In geographic location, studies were categorized into 1 of 6 geographical locations according to the traditional Chinese administrative regions: East China, Northeast, North China, South China, Central China, Northwest, and Southwest. In economic development level, studies were categorized as 3 groups by per capita GDP in 2016, which included low, moderate, and high level. HPV assay method mainly contained PCR & hybridization, real‐time PCR, and sequencing PCR. Type of HPV infection included high risk HPV or low risk HPV, single infection or multiple infection, and the top 10 HPV infection subtypes.

3. RESULTS {#cam42017-sec-0008}
==========

3.1. Search results {#cam42017-sec-0009}
-------------------

A total of 45 907 studies were found through searching the database (MEDLINE: 2005, Web of Science: 1312, CQVIP: 10903, CNKI: 8845 and Wanfang: 22842). First, the Endnote® bibliographic software was used to identify the duplicated studies, 34 736 studies were removed. Second, 9381 studies were removed by reading title or abstracts, which included the studies related to HPV and cancers, reviews, and genetic polymorphisms. Third, 1598 studies were removed by reading full text. In the remaining 192 papers, a total of 94 studies contained outpatients and/or patients, 16 studies did not provide sufficient data to calculate the prevalence of HPV, and 14 studies were from the same population. Finally, the remaining 68 population‐based studies (English studies: 34; Chinese studies: 34) satisfied the inclusion criteria for our study. A flow chart of the screening process is shown in Figure [1](#cam42017-fig-0001){ref-type="fig"}.

![The flow chart of screening process in our meta‐analysis](CAM4-8-5373-g001){#cam42017-fig-0001}

3.2. The characteristics of the included studies {#cam42017-sec-0010}
------------------------------------------------

In the included studies, we found there were 31 provinces which reported the prevalence of HPV infection in general population, except for Gansu, Jilin, and Guizhou. The number of studies reported in 10 provinces was over 3. A total of 1705956 people were included in our study, the number of people in each province ranged from 1008 to 714 235. The prevalence of HPV infection ranged from 6.2% (Hong Kong) to 31.3% (Hainan). The characteristic of the included studies was in Table [1](#cam42017-tbl-0001){ref-type="table"}. Figure [2](#cam42017-fig-0002){ref-type="fig"} showed the number of studies, the sample size, and the prevalence on HPV infection in each province.

###### 

The characteristic of the included studies

  Author           Year of publication   Number of subjects   Age            Study period      The definition of HPV POSITIVITY   The specimen type   HPV assay method                           Region classification   Province         City                                                                                                       The quality score
  ---------------- --------------------- -------------------- -------------- ----------------- ---------------------------------- ------------------- ------------------------------------------ ----------------------- ---------------- ---------------------------------------------------------------------------------------------------------- -------------------
  Jin, LM          2018                  116441               21‐78          2013‐2016         HPV DNA                            Exfoliated cells    Sequencing PCR                             city                    Shanghai                                                                                                                    **9**
  Zhang, C         2018                  33562                11‐96          2016.1‐2016.12    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Shanghai                                                                                                                    9
  Wang, X          2018                  5655                 17‐68          2014.4‐2015.12    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Inner Mongolia                                                                                                              9
  Dong, L          2017                  1997                 35‐45          1999.6            HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Shanxi           Xianghua                                                                                                   9
  Zhou, X. H       2017                  2452                 20‐80          2013.3‐2013.12    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Shanghai                                                                                                                    9
  Xu, H. H         2017                  37967                15‐90          2012.12‐2016.2    HPV DNA                            Exfoliated cells    Real‐time PCR                              city                    Zhejiang         Taizhou                                                                                                    8
  Zhong, TY        2017                  714235               16‐77          2010.8‐2015.12    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Jiangxi          Nanchang, Jiu‐jiang, Yingtan, Jingdezhen, Shangrao, Yichun, Xinyu, Pingxiang,Fuzhou, Ji\'an, and Ganzhou   9
  Wu, X            2017                  2300                 18‐45          2013.3‐2013.7     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangxi          Liuzhou                                                                                                    9
  Abulizi, G.      2017                  6000                 21‐60                            HPV DNA                            Exfoliated cells    Real‐time PCR                              rural                   Xinjiang         Uyghur                                                                                                     9
  Zhang, J         2017                  58650                13‐81          2012.6‐2016.5     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Sichuan          Chengdu                                                                                                    8
  Qi, ZW           2017                  4250                 18‐69          2013.1‐2016.1     HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          Hebei            Chengde                                                                                                    8
  Shen, XP         2017                  20000                35‐64          2015              HPV DNA                            Exfoliated cells    Real‐time PCR                              rural                   Ningxia                                                                                                                     7
  Zhang Xiaohong   2017                  38408                Not reported   2012.3‐2015.12    HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          Shaanxi                                                                                                                     7
  Yang, DM         2017                  9001                 22‐84          2016.1‐2016.12    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Hunan            Changsha                                                                                                   8
  Jin, DC          2017                  50502                18‐50          2015.1‐2015.12    HPV DNA                            Exfoliated cells    Real‐time PCR                              city                    Henan            Zhengzhou                                                                                                  8
  Baloch, Z        2016                  17898                18‐93          2013.10‐2015.2    HPV DNA                            Exfoliated cells    Sequencing PCR                             city and rural          Yunnan                                                                                                                      9
  Gu, Y            2016                  10501                39‐55          2014.1‐2015.5     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Shanghai                                                                                                                    9
  Liu, F           2016                  2187                 25‐65          2007‐2009         HPV DNA                            Exfoliated cells    Sequencing PCR                             rural                   Henan            anyang                                                                                                     9
  Wei, F           2016                  2378                 18‐55          2014.5‐2014.7     HPV DNA                            Exfoliated cells    Real‐time PCR                              city                    Guangxi          Liuzhou                                                                                                    8
  Zeng, XX         2016                  8284                 18‐65          2012.1‐2012.12    HPV DNA                            Exfoliated cells    Sequencing PCR                             city                    Guangdong        Heyuan                                                                                                     9
  Niyazi, M        2016                  883                  15‐54          2006.9            HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Xinjiang         Hetian                                                                                                     8
  Zhang, Y         2016                  3000                 30‐59          2015.3‐2015.6     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangdong        Shenzhen                                                                                                   8
  Que, M           2016                  21078                35‐64          2014              HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Anhui                                                                                                                       8
  Ji,HY            2016                  5892                 18‐80          2013.10‐2015.10   HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          Qinghai                                                                                                                     9
  Long, Xin        2016                  29580                16‐81          2010.11‐2015.9    HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          Chongqing                                                                                                                   9
  Wang, JX         2015                  191829               35‐65          2013              HPV DNA                            Exfoliated cells    PCR & (mass‐spectrometric detection) MSD   city                    Jiangsu          Wuxi                                                                                                       8
  Mijit, F         2015                  4500                 20‐69          2008.6‐2008.9     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Xinjiang         Hetian                                                                                                     8
  Zhao, Y          2015                  6273                 17‐59          2004.5‐2007.4     HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          ---              Beijing, Shanghai, Shenzhen, Shenyang, Shanxi, Henan, Xinjiang                                             10
  Chen, X          2015                  2000                 21‐65          2013.4‐2013.10    HPV DNA                            Exfoliated cells    Sequencing PCR                             city                    Tianjin                                                                                                                     8
  Hong, H          2015                  1373                 22‐64          2012.4‐2012.6     HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Zhejiang         Ningbo                                                                                                     8
  Yang, L          2015                  9,460                Not reported   Not reported      HPV DNA                            Exfoliated cells    Not reported                               city                    Shandong         Weihai                                                                                                     8
  Zhao, Q          2015                  24817                18‐80          2012.7‐2013.7     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Hunan                                                                                                                       9
  Li, XL           2015                  1008                 23‐78          2014.8‐2014.10    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Hubei            Yichang                                                                                                    9
  Chen, MH         2014                  11231                25‐74          2012.1‐2012.12    HPV DNA                            Exfoliated cells    Sequencing PCR                             city                    Jiangsu          Wuxi                                                                                                       8
  Jing, L          2014                  78355                18‐75          2011.5‐2012.11    HPV DNA                            Exfoliated cells    Real‐time PCR                              city                    Guangdong                                                                                                                   9
  Zhu, MH          2014                  7796                 18‐70          2012.3‐2012.7     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangdong        Huizhou                                                                                                    8
  Pei, YY          2014                  1944                 20‐67          Before 2014       HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangdong        Shenzhen                                                                                                   7
  Yang, L          2013                  1759                 24‐77          2010.6‐2010.10    HPV DNA                            Exfoliated cells    Real‐time PCR                              city                    Heilongjiang     Daqing                                                                                                     8
  Wu, EQ           2013                  4,215                17‐54          2006.5‐2007.4     HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          ---              Beijing, Shanghai, Shanxi, Henan, and Xinjiang                                                             10
  Zhang, R         2013                  10000                17‐89          2011.3‐2011.5     HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Shanghai         Fengxian                                                                                                   9
  Wu, XQ           2013                  4228                 19‐59          2011.11‐2012.4    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangdong        Guangzhou                                                                                                  8
  Weng, ZC         2013                  1029                 Not reported   2010.10‐2012.5    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Hainan           Haikou                                                                                                     7
  Wu, D            2013                  2050                 15‐91          2010.1‐2012.11    HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Beijing                                                                                                                     8
  Wang, S          2012                  24041                18‐60          2007‐2010         HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Liaoning                                                                                                                    9
  Wang, Y          2012                  3052                 20‐79          2011.3‐2012.3     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Fujian                                                                                                                      8
  ZhangJing        2012                  3685                 29‐67          2010.7‐2011.6     HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Shaanxi                                                                                                                     8
  Chen, JC         2012                  3399                 26‐59          2010.1‐2011.4     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangdong        Shantou                                                                                                    8
  Wang, YY         2012                  9683                 Not reported   2006.4‐2010.4     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangdong        Shenzhen                                                                                                   7
  Zhao, R          2011                  5552                 25‐54          2006.9‐2008.12    HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          Beijing                                                                                                                     9
  Liu, SS          2011                  1570                 Not reported   2007.1‐2008.4     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Hong Kong                                                                                                                   9
  Ablimit, T       2011                  400                  26‐65          2008.7‐2008.9     HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Xinjiang         Hetian                                                                                                     7
  Liu, JX          2011                  4874                 24‐55          2008.7‐2010.12    HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          Guangxi                                                                                                                     8
  Chen HC          2011                  10602                30‐65          1991‐1992         HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Taiwan                                                                                                                      9
  Yip, Y. C        2010                  1600                 20‐60          2008.5‐2008.8     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Macao                                                                                                                       8
  Ye, J            2010                  4987                 20‐79          2007.11‐2008.8    HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Zhejiang                                                                                                                    9
  Wu, D            2010                  2338                 20‐70          2008.5‐2009.5     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Fujian           Fuzhou                                                                                                     9
  Jiang, Y         2010                  4911                 20‐69          2008.4‐2008.9     HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          Fujian           Xiamen                                                                                                     8
  Zhouyuan         2010                  20905                14‐84          2008.10‐2009.3    HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural          Zhejiang                                                                                                                    9
  Jin, Q           2009                  3036                 19‐65          2007.8            HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Xizang           Lhasa, Shigatse, Nagqu                                                                                     9
  Li, N            2008                  2374                 15‐59          2004.5‐2006.9     HPV DNA                            Exfoliated cells    PCR & hybridization                        city and rural                           Shanxi, Guangdong, Liaoning                                                                                10
  Chao A           2008                  10014                30‐            2004.6‐2005.6     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Taiwan                                                                                                                      9
  Zhang, X         2007                  702                  19‐59          2006.8‐2006.9     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Liaoning         Shenyang                                                                                                   9
  Dai, M           2006                  662                  15‐59          2004.3‐2004.4     HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Shanxi                                                                                                                      9
  Li, LK           2006                  685                  15‐59          2005.6‐2005.7     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Liaoning         Shenyang                                                                                                   9
  Shi, JF          2006                  1137                 15‐59          Before 2006       HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangdong        Shenzhen                                                                                                   9
  Wu, KH           2004                  500                  21‐45          1999.7‐2001.6     HPV DNA                            Exfoliated cells    PCR & hybridization                        city                    Guangdong        Guangzhou                                                                                                  8
  Chen Feng        2004                  3233                 30‐50          2002              HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Shanxi                                                                                                                      8
  Shen Yanhong     2003                  9683                 30‐50          Before 2003       HPV DNA                            Exfoliated cells    PCR & hybridization                        rural                   Shanxi                                                                                                                      8

Because the number of references was too much, the authors made the references of the included studies in Supplementary Data [S2](#cam42017-sup-00021){ref-type="supplementary-material"}.
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![The number of studies, the sample size, and the prevalence on Human papillomavirus (HPV) infection in each province of China](CAM4-8-5373-g002){#cam42017-fig-0002}

We assessed the quality of included studies using the modified quality assessment tool. The quality scores of the included studies were shown in Table [1](#cam42017-tbl-0001){ref-type="table"}. The quality scores ranged from 7 to 11 and 10. Only 6 studies were assessed as moderate quality, and all other studies were assessed as high quality.

3.3. The infection of HPV in Chinese women {#cam42017-sec-0011}
------------------------------------------

In the included studies, there were 71 databases that reported the overall prevalence of HPV infection, the national overall prevalence of HPV infection was 15.54% (95% CI: 13.83%‐17.24%); there were 50 databases that reported HPV infection in urban, the prevalence of HPV infection was 14.86% (95% CI: 12.84%‐16.88%), and there were 21 databases that reported HPV infection in rural, the prevalence of low risk HPV infection was 13.70% (95% CI: 11.18%‐16.22%).

According to the traditional geographical regions of China, we have divided China into seven regions, which included East China, North China, Central China, South China, Southwest, Northwest, and Northeast, the prevalence of HPV infection were 15.99% (95% CI: 12.84%,‐19.13%), 18.43% (95% CI: 13.39%‐23.46%), 12.96% (95% CI: 8.44%‐17.48%), 13.51% (95% CI: 11.34%‐15.68%), 12.92% (95% CI: 5.31%‐20.53%), 12.57% (95% CI: 8.49%‐16.65%), and 19.85% (95% CI: 3.46%‐36.23%), respectively. According to the level of GDP per capita in 2016, China was categorized into 3 groups, namely, low, middle, and high, the prevalence of HPV infection were 16.72%(95% CI: 13.81%‐19.62%), 18.01%(95% CI: 12.67%‐23.35%), and 13.41%(95% CI: 11.74%‐15.09%). According to HPV assay method, the prevalence of HPV infection was 16.55% by PCR and hybridization and the prevalence of HPV infection was 11.73% by sequencing or real‐time PCR.

There were 66 databases that reported the prevalence of high risk HPV infection, the prevalence of high risk HPV infection was 11.93% (95% CI: 10.93%‐12.92%), and there were 46 databases that reported the prevalence of low risk HPV infection, the prevalence of low risk HPV infection was 2.78% (95% CI: 2.35%‐3.20%); there were 35 databases that reported the prevalence of single HPV infection, the prevalence of single HPV infection was 11.00% (95% CI: 9.32%‐12.68%), and there were 48 databases that reported the prevalence of multiple HPV infection, the prevalence of multiple HPV infection was 3.44% (95% CI: 2.69%‐4.18%), the multiple HPV infection included dual infection (2.30%, 95% CI: 2.01%‐2.58%), triple infection (0.51%, 95% CI: 0.42%‐0.60%), fourfold infection (0.11%, 95% CI: 0.07%‐0.15%), and fivefold infection (0.04%, 95% CI: 0.01%‐0.07%), respectively. In the detection of the HPV subtype, we found that HPV16, 52, 58, 18, and 33 are the top 5 subtypes, and the prevalence of the top 5 subtypes was 3.52% (95% CI: 3.18%‐3.86%), 2.20% (95% CI: 1.93%‐2.46%), 2.10% (95% CI: 1.88%‐2.32%), 1.20% (95% CI: 1.05%‐1.35%), 1.02% (95% CI: 0.89%‐1.14%).

We further stratified the analysis by age, found that there were 12 databases which reported the prevalence of high risk HPV infection by age. Because of different age groups in databases, 12 databases were divided into 3 groups for analysis. In group 1, the prevalence of HPV infection in \<25, 55‐59, 60‐65 age groups were higher with 13.31%, 14.93%, and 16.33%, respectively, and that in 25‐29, 30‐34 age groups were lower with 9.97% and 9.50%, respectively. In group 2, the prevalence of HPV infection in \<25, \>65 age groups were higher with 19.21% and 13.33%, respectively, and that in 25‐34, 55‐64 age groups were lower with 9.95% and 9.84%, respectively. In group 3, the prevalence of HPV infection in \<25, \>60 age groups were higher with 33.37% and 26.03%, respectively, and that in 31‐40, 41‐50 age groups were lower with 13.94% and 13.86%, respectively.

In the included studies, the year of the epidemiological investigation ranged from 1991 to 2016. There was only one study that reported 1991, 1992, 1999, 2000, 2001, 2002, and 2003, the number of studies which reported other years were at least 4 or more. Therefore, we pooled 7 datasets that reported 1991, 1992, 1999, 2000, 2001, 2002, and 2003, to get more stable result. Except for the higher prevalence of HPV infection in 2009 and 2010, the prevalence of HPV infection in other years changed little, ranged from 13.2% to 17.4%. Figure [3](#cam42017-fig-0003){ref-type="fig"} showed the time trend of HPV infection between 2003 and 2016.

![The time trend of Human papillomavirus (HPV) infection between 2003 and 2016](CAM4-8-5373-g003){#cam42017-fig-0003}

4. DISCUSSION {#cam42017-sec-0012}
=============

The prevalence of HPV infection varied geographically, and the prevalence of cervical infection with human papillomavirus (HPV) in women also varies greatly worldwide. In order to understand the situation of HPV infection in Chinese women accurately, we conducted a pooled analysis of 68 population‐based studies, which contained 1 705 956 subjects. As far as we know, this is the most comprehensive and extensive, HPV‐related study in China. The national overall prevalence of HPV infection was 15.54% (95% CI: 13.83%‐17.24%), which ranged from 6.2% (Hong Kong) to 31.3% (Hainan) and varied by region. This may be due to the large Chinese population and its territories. Meanwhile, age, economic conditions, cultural habits, and population migrations might also influence factors.[12](#cam42017-bib-0012){ref-type="ref"} Therefore, we further carried out subgroup analysis by different regions and economic levels. The results from our study indicated that the prevalence of HPV infection in urban was similar to that in rural. A high burden of HPV infection was found in East, North, and Northeast region of China. The higher prevalence of HPV infection was found in middle and high economic level. The prevalence of high risk HPV infection, the prevalence of high risk HPV infection (11.93%) was as 4 times as high as that of low risk HPV infection (2.78%). We also analyzed the HPV infection epidemiological trend between 2003 and 2016, and found that the prevalence of HPV infection were higher in 2009 and 2010, the prevalence of HPV infection in other years changed little, ranged from 13.2% to 17.4%.

The prevalence of single infection was 11.00% (95% CI: 9.32‐%‐12.68%) while the prevalence of multiple infection was 3.44% (95% CI: 2.69%‐4.18%). In the multiple HPV infection individuals, the frequencies of 5, 4, 3, and 2 genotypes were 0.04%, 0.11%, 0.51%, and 2.30%, respectively. We found that the main form of HPV infection was single infection, and multiple HPV infections were less common, the results were consistent with previous studies. Some studies had suggested that multiple HPV infections could potentially have competitive and/or cooperative interactions between HPV genotypes. Multiple HPV infections would increase the duration of infection, and patients with multiple high viral loads showed a fourfold to sixfold increased risk of cervical precancerous cytological lesions compared with patients with single high viral loads. There was an association between infection with multiple HPV types and an increased risk of cervical cancer. The mechanisms and potential oncogenic effects of multiple infections warrant further investigation, which could be useful in the development of HPV prophylactic vaccines.

In 2009, on the evidence of epidemiological and biological research, International Cancer Research Institute (IARC) defined 12 HPV types as HPV 16, 18, 31, 33, 35,39, 45, 51, 52, 58, and 59 as carcinogenic HPV (I carcinogen), and defined HPV 68 as a potentially carcinogenic HPV (2A carcinogen). HPV 26, 53, 66, 67, 67, 82, etc, which may be carcinogenic, were defined as Carcinogenic HPV (2B carcinogen).The carcinogenic HPV clustered in 4 species groups of the alpha genus, which included HPV 51 in species 5, HPV 56 in species 6, HPV 18, 39, 45, and 59 in species 7 and HPV 16, 31, 33, 35, 52, and 58 in species 9.[13](#cam42017-bib-0013){ref-type="ref"} Based on WHO worldwide data, the 5 most frequent HPV types in the general female population are HPV 16, 18, 31, 58, and 52. HPV 16, 18, 58, 31, and 33 are the most common in America, while the 5 most frequent HPV types in Europe were HPV 16, 18, 31, 33, and 58.[14](#cam42017-bib-0014){ref-type="ref"} In our study, HPV 16, 52, 58, 18, and 33 are the top 5 HPV infection subtypes in China, the distribution of which was different from other regions in the world. We also found that except HPV 18, HPV 16, 52, 58, and 33 was in species 9 of the alpha genus. HPV 16 and HPV 18 are well known as oncogenic genotypes and account for about 70% of invasive cervical cancers (ICC) worldwide. Though more variation in the ranking of individual types was in different countries, HPV 33, 45, 31, 58, 52, and 35 make up the rest of the top 8.[15](#cam42017-bib-0015){ref-type="ref"} For the Chinese women, Bao YP, et al found that in high‐grade squamous intraepithelial lesions (HSIL) and low‐grade squamous intraepithelial lesions (LSIL) samples, HPV 16, 58, 52, 18, and 33 were the most commonly detected types after adjusting for confounding factors (geographic area, classification of cervical disease status, and HPV testing method).[16](#cam42017-bib-0016){ref-type="ref"}Zhou HL, et al found that in invasive carcinoma of cervix (ICC), the top 5 common HPV types were HPV 16, 18, 58, 52, and 33 in descending order of frequency. The present prophylactic vaccine for cervical cancer is developed based on the results of the HPV epidemiological survey abroad. In China, the quadrivalent vaccine (HPV 16, 18, 6, and 11) and the bivalent vaccine (HPV 16 and 18) were licensed. In our study, the top 5 common HPV types were HPV 16, 18, 58, 52, and 33 in Chinese general population. Therefore, the quadrivalent and bivalent vaccines were unable to cover the common HPV infection types in China, could not provide effective protection for cervical cancer.

In age group, we found that the prevalence of HPV infection in \<20 and \<25 age groups were high, then there was a distinct decline. When the age reached 60 or even older, the prevalence of HPV infection had increased again. The high prevalence of HPV infection in younger women may be related to unhealthy sexual habits such as premature sexual life, excessive frequency, and excessive sexual partners.[17](#cam42017-bib-0017){ref-type="ref"} Although the prevalence of HPV infection in young women is high, most of HPV infection may be cleared automatically within 1‐2 years, so the prevalence of HPV infection would be reduced. The immune ability declined with age in old women, especially in the premenopausal and postmenopausal women, the ability in eliminating previous and new infections weakened, so the high prevalence of HPV infection was also in older women.[18](#cam42017-bib-0018){ref-type="ref"}

There were several limitations in our meta‐analysis. First, because our study aims to reflect the HPV prevalence in general population. In the process of detecting HPV for cervical cancer screening, cervical high‐grade lesions, and cancer might be screened out, we should analyze the prevalence of HPV in cervical high‐grade lesions and cancer. But, in process of collecting the included studies, we found that only a few studies reported the number of cervical high‐grade lesions and cancer, fewer studies reported the prevalence of HPV in cervical high‐grade lesions and cancer was too small, most of studies did not report the prevalence of HPV infection in cervical high‐grade lesions and cancer. We could not analyze the prevalence of HPV infection in cervical high‐grade lesions and cancer. Second, different detection methods might have different effects on the detection rate of HPV infection, and might affect the prevalence of HPV infection. Therefore, we performed subgroup analysis by the HPV assay method, the prevalence of HPV infection was 16.55% by PCR & hybridization, and the prevalence of HPV infection was 11.73% by sequencing or real‐time PCR. The HPV assay method might be the heterogeneity source of the prevalence of HPV infection, it deserved our attention in the follow‐up studies. Third, in our study, we had considered the effects of many factors on the prevalence of HPV infection in our study. Because our included studies did not report standardized rate, when we merged the prevalence of HPV infection, we just only focused on the description of the results, could not compare.

In conclusion, HPV type in Chinese women was quite distinctive. HPV infection played a critical role in the occurrence of cervical cancer, which affected by geographical region, economic conditions, cultural habits, and population migrations. In the screening process of cervical cancer, we should pay attention to mental stress, destruction of the cervical tissue by invasive operation and economic burden caused by over diagnosis and treatment, when improving the sensitivity of screening and reducing the missed diagnosis rate were emphasized. Understanding the distribution of HPV type and performing the HPV type testing had important clinical value for colposcopy referral and increasing the detection rate. Therefore, our findings could provide evidence for cervical cancer screening and vaccine, in order to reduce the burden of cervical cancer.
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###### 

The pooled prevalence of Human papillomavirus (HPV) infection in Chinese women

                                Number of databases   Number of Subjects   Prevalence (%)   95% CI
  ----------------------------- --------------------- -------------------- ---------------- -------------
  Overall                       71                    1705956              15.54            13.83‐17.24
  Subgroup Analysis                                                                          
  Areas                                                                                      
  Urban                         50                    1488733              14.86            12.84‐16.88
  Rural                         21                    113946               13.70            11.18‐16.22
  East China                    18                    1197096              15.99            12.84‐19.13
  North China                   13                    35761                18.43            13.39‐23.46
  Central China                 5                     79393                12.96            8.44‐17.48
  South China                   20                    155199               13.51            11.34‐15.68
  Southwest                     4                     109164               12.92            5.31‐20.53
  Northwest                     9                     80651                12.57            8.49‐16.65
  Northeast                     6                     33552                19.85            3.46‐36.23
  GDP                                                                                        
  High                          36                    631416               13.41            11.74‐15.09
  Middle                        15                    178795               18.01            12.67‐23.35
  Low                           22                    859989               13.48            11.57‐15.39
  HPV Assay Method                                                                           
  PCR & hybridization           57                    1167563              16.55            14.53‐18.56
  Sequencing or real‐time PCR   12                    337104               11.73            9.34‐14.11
  HPV types                                                                                  
  High risk HPV                 66                    1426787              11.93            10.93‐12.92
  Low risk HPV                  46                    1176995              2.78             2.35‐3.20
  HPV infection types                                                                        
  Single infection              35                    1424052              11.00            9.32‐12.68
  Multiple infection            48                    1419715              3.44             2.69‐4.18
  Dual infection                14                    445316               2.30             2.01‐2.58
  Triple infection              13                    442280               0.51             0.42‐0.60
  Fourfold infection            9                     406238               0.11             0.07‐0.15
  Fivefold infection            5                     204499               0.04             0.01‐0.07
  The top 10 subtypes                                                                        
  HPV 16                        68                    1604203              3.52             3.18‐3.86
  HPV52                         65                    1574238              2.20             1.93‐2.46
  HPV58                         65                    1579921              2.10             1.88‐2.32
  HPV18                         60                    1566134              1.20             1.05‐1.35
  HPV33                         54                    1524449              1.02             0.89‐1.14
  HPV31                         52                    1467424              0.84             0.74‐0.95
  HPV51                         50                    1487714              0.72             0.64‐0.81
  HPV 56                        49                    1415424              0.66             0.57‐0.74
  HPV6                          48                    1500726              0.63             0.48‐0.78
  HPV11                         45                    1506233              0.56             0.43‐0.69
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###### 

The pooled prevalence of Human papillomavirus (HPV) infection by age group

  Age group   Number of databases   Number of Subjects   Prevalence (%)   95% CI
  ----------- --------------------- -------------------- ---------------- -------------
  Group 1                                                                  
  \<25        4                     3273                 13.31            7.33‐19.28
  25‐29       4                     13619                9.97             6.89‐13.04
  30‐34       4                     22629                9.50             6.53‐12.47
  35‐39       4                     27780                10.38            7.66‐13.10
  40‐44       4                     30320                10.58            7.97‐13.19
  45‐49       4                     26892                10.24            8.19‐12.29
  50‐54       4                     32050                12.29            10.45‐14.13
  55‐59       2                     31302                14.93            7.96‐21.90
  60‐65       2                     10953                16.33            3.01‐29.65
  66‐70       1                     5302                 10.37            9.55‐11.19
  Group 2                                                                  
  \<25        3                     876                  19.21            10.62‐27.79
  25‐34       3                     6463                 9.95             3.46‐16.43
  35‐44       3                     8782                 12.54            7.26‐17.82
  45‐54       2                     1900                 12.03            3.14‐20.92
  55‐64       2                     270                  9.84             2.51‐17.18
  \>65        1                     30                   13.33            1.17‐25.49
  Group 3                                                                  
  \<20        2                     1732                 33.37            17.67‐49.07
  21‐30       5                     31403                14.65            8.40‐20.89
  31‐40       5                     48829                13.94            8.03‐19.85
  41‐50       5                     52141                13.86            7.58‐20.14
  51‐60       4                     21496                18.89            10.74‐27.03
  \>60        2                     2342                 26.03            24.26‐27.81
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